- Market Capitalization, $K 358,685
- Shares Outstanding, K 167,610
- Annual Sales, $ 44,510 K
- Annual Income, $ -70,480 K
- 60-Month Beta 1.37
- Price/Sales 8.36
- Price/Cash Flow N/A
- Price/Book 5.40
|Period||Period Low||Period High||Performance|
| || |
-0.03 (-1.38%)since 11/05/19
| || |
+0.37 (+20.90%)since 09/05/19
| || |
-0.73 (-25.44%)since 12/04/18
The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 London Healthcare Conference...
Pharma sector wins in October, making these ETFs and stocks winners.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets has been accepted for two poster presentations at the 61st American...
Rigel (RIGL) delivered earnings and revenue surprises of 36.36% and 28.19%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $11.5 million in its third quarter.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2019, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for...
Palm Beach, FL -October 29, 2019 - Acute myeloid leukemia (AML), is the most common of the four major types of leukemia. Without treatment, AML is often deadly within a few months. Many of the symptoms...
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2019 financial results after market close on Tuesday, November 5, 2019. Rigel senior management will follow...
|Micro-Cap Ishares ETF|
|Principal Healthcare Innovators Index|
|Nasdaq Biotechnology Ishares ETF|
|Russell 2000 Growth Ishares ETF|
|Russell 2000 Growth Vanguard|